MentionFox
Home › Who owns › Kura Oncology, Inc.
Owners, funding and legal record

Who owns Kura Oncology, Inc.? Owners, funding and legal record

Before you sign with, sell to or invest in Kura Oncology, Inc.

MentionFox check on Kura Oncology, Inc.: no red flags found in 16 sources (checked 20 November 2026). mentionfox.com/c/who-owns/kura-oncology-inc

Check Kura Oncology, Inc. before you sign, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Kura Oncology, Inc.?

Kura Oncology, Inc. is a publicly traded company (Nasdaq: KURA). The most recent 5%+ ownership report names BVF Partners holding 7.5% (Schedule 13G/A, filed 2026-11-16).

As of November 20, 2026, Kura Oncology, Inc. is a publicly traded company (Nasdaq: KURA); its largest reported holder is Montanova Capital, LLC, with 9.7% on Schedule 13G/A of August 14, 2026, then BlackRock (8.9%). The largest insider holding is Troy Wilson, the chief executive and president, with 1,414,650 shares (1.5% of shares outstanding), per Form 4/A of November 17, 2026 (Schedule 13G/A, August 14, 2026).

Faheem Hasnain is also named on 1 other Form D filing ↓

Is this your company?

About to sign with, pay or invest in Kura Oncology, Inc.? See the free Snapshot first.

Watch Kura Oncology, Inc.

Free to see. No signup.

Is Kura Oncology, Inc. a real, registered company?

Before you sign or pay

Who are Kura Oncology, Inc.'s owners and officers?

Kura Oncology, Inc.: incorporated in Delaware; business address in San Diego, California; industry Pharmaceutical Preparations (Form D, 2026-11-18).

Officers and directors, each with the role and the filing that names them:

ReportHolderShare
Schedule 13G/A, 2026-11-16Bvf Partners L P/Il7.5%
Schedule 13G/A, 2026-10-27Blackrock, Inc.8.9%
Schedule 13G/A, 2026-08-14Montanova Capital, LLC9.7%
Schedule 13G/A, 2026-05-15Armistice Capital, LLC4.23%
Schedule 13G, 2026-04-30Vanguard Capital Management5.01%
Schedule 13G/A, 2026-03-27The Vanguard Group0%
Schedule 13G/A, 2026-02-17Armistice Capital, LLC5.67%
Schedule 13G, 2026-02-09State Street Corporation5.7%
Schedule 13G/A, 2025-11-14Armistice Capital, LLC5.37%
Schedule 13G/A, 2025-11-14Bvf Partners L P/Il9.99%
Schedule 13G/A, 2025-08-15Armistice Capital, LLC7.14%
Schedule 13G/A, 2025-08-14Ecor1 Capital, LLC4.8%

Questions about who owns Kura Oncology, Inc.

Who owns Kura Oncology, Inc.?

On this page, 5 holders' latest ownership filings report 5% or more of Kura Oncology, Inc.: Montanova Capital, LLC (9.7%, Schedule 13G/A, filed 2026-08-14), Blackrock, Inc. (8.9%, Schedule 13G/A, filed 2026-10-27), Bvf Partners L P/Il (7.5%, Schedule 13G/A, filed 2026-11-16), State Street Corporation (5.7%, Schedule 13G, filed 2026-02-09) and Vanguard Capital Management (5.01%, Schedule 13G, filed 2026-04-30).

Who are the largest shareholders of Kura Oncology, Inc.?

By the share each holder's latest filing reports, the largest holders of Kura Oncology, Inc. on this page are Montanova Capital, LLC (9.7%), Blackrock, Inc. (8.9%) and Bvf Partners L P/Il (7.5%).

When did Montanova Capital, LLC buy into Kura Oncology, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Montanova Capital, LLC on this page is the Schedule 13G/A, filed 2026-08-14, reporting 9.7%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Want the whole picture on Kura Oncology, Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Kura Oncology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Kura Oncology, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    21 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.
FiledPersonRoleChangeEffective
Form 8-K, 2026-09-08Jennifer FulkChief Financial Officerappointed2026-09-08

Which insiders own Kura Oncology, Inc. shares?

Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.

Shares outstanding: 91,878,694 as of 2026-11-06, from the company's latest SEC cover page.

How much has Kura Oncology, Inc. raised?

FiledSoldOffered
Form D, 2026-11-18$5M$25M
Form D, 2024-02-05$150M$150M

Keep reading

More on Kura Oncology, Inc. and the records around it.

The people at Kura Oncology, Inc.

Kura Oncology, Inc. elsewhere on the record

Companies that share a holder

Related pages

Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.

Not for employment, credit, insurance or tenancy decisions.

Cite this page

Permanent URL: https://mentionfox.com/who-owns/kura-oncology-inc
Last updated 2026-11-20
Who owns Kura Oncology? Publicly traded (Nasdaq: KURA). MentionFox, 2026-11-20. https://mentionfox.com/who-owns/kura-oncology-inc